Similar to a number of recent studies19,20, we have demonstrated in this cohort of PanNETs that, in additional to pathologic stage and grade of the tumor, mutations in DAXX, ATRX, and MEN1 are associated with adverse clinical outcome in comparison to those without these mutations. Here, ATRX is linked to neoplasm.